Avenue Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-11.65	-10.38	-3.55	-3.73	-5.15	Upgrade
Asset Writedown & Restructuring Costs	-	3	-	-	-	Upgrade
Stock-Based Compensation	1.24	0.91	0.65	0.44	0.71	Upgrade
Other Operating Activities	1.21	-2.69	-5.1	-	-	Upgrade
Change in Accounts Receivable	-	-	0.09	-0.09	-	Upgrade
Change in Accounts Payable	0.19	-0.36	0.35	-0.38	-0.23	Upgrade
Change in Other Net Operating Assets	-0.01	0.07	-0.03	0.01	0.06	Upgrade
Operating Cash Flow	-9.03	-9.45	-7.6	-3.75	-4.61	Upgrade
Sale (Purchase) of Intangibles	-	-3	-	-	-	Upgrade
Other Investing Activities	-	-	-	-	-1	Upgrade
Investing Cash Flow	-	-3	-	-	-1	Upgrade
Issuance of Common Stock	11.04	7.53	11.65	5.04	-	Upgrade
Repurchase of Common Stock	-	-	-1.1	-	-	Upgrade
Other Financing Activities	-1.21	-	-	-0.66	-	Upgrade
Financing Cash Flow	9.84	7.53	10.54	4.38	-	Upgrade
Net Cash Flow	0.81	-4.93	2.95	0.63	-5.61	Upgrade
Levered Free Cash Flow	-6.21	-13.49	-1.25	-2.36	-3.72	Upgrade
Unlevered Free Cash Flow	-6.21	-13.49	-1.25	-2.36	-3.72	Upgrade
Change in Net Working Capital	0.39	2.31	-3.13	0.46	1.17	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.